Please login to the form below

Not currently logged in
Email:
Password:

Sudler & Hennessey Australia hire new MD

Sudler & Hennessey (S&H) have appointed Jack Blakey as managing director of their operation in Australia

Global healthcare marketing and communications organisation, Sudler & Hennessey, have appointed Jack Blakey as managing director of their operation in Australia.

The news follows the promotion of Max Jackson to CEO of both S&H's Europe/Middle East/Africa (EMEA) and Asia Pacific (APAC) regions.

Max Jackson, CEO of the S&H EMEA and APAC regions, said: "We have been looking for an exceptional individual who can work with our talented team to continue to deliver the work that our clients expect. I am delighted to announce we have successfully completed that search with the appointment of Jack. With his depth and breadth of proven talents and skills, Jack can deliver an exciting new chapter in the agency's already successful history."

Prior to joining S&H, Blakey had been running his own agency, Marrow, whose major clients include AstraZeneca and Roche as well as health related brands in food, financial services and publishing. 

18th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics